Axillary Staging in Early Breast Cancer: SNB vs PET/MRI
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04829643 |
|
Recruitment Status :
Recruiting
First Posted : April 2, 2021
Last Update Posted : April 2, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The gold standard of surgical treatment for patients with early breast cancer (BC) is breast conservation and sentinel node biopsy (SNB). Ongoing randomized trials are evaluating to omit surgery at all when axillary imaging is negative. However, the available diagnostic tools still have several limitations in accuracy.
Combining the specificity of PET, with the superior sensitivity of MRI, hybrid PET/MRI might be a non-invasive, one-stage, operator-independent imaging method to accurately define nodal status and, whenever negative, might replace surgery for axillary staging.
The project includes patients with <3 cm BC without overt nodal involvement who will undergo PET/MRI prior to surgery. The primary aim is to compare the staging power between SNB and PET/MRI in detecting axillary lymph node macrometastases (>2 mm). Additionally, general concordance and diagnostic accuracy of PET/MRI vs SNB, eventual correlation with BC molecular subtypes and MRI findings will be evaluated.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Breast Cancer Sentinel Lymph Node Early-stage Breast Cancer | Diagnostic Test: PET/MRI | Not Applicable |
SNB is the gold standard for axillary staging in early BC patients. Although being a minimally invasive, it is time consuming both for surgeon and pathologist, it may add a further scar and is not free from complications: seroma, limitation of shoulder movement, nerve injury, lymphedema. To date, patients undergoing breast conserving surgery (BCS) with 1 to 2 positive nodes can be treated with SNB alone (ACOSOG Z011 trial NCT00003855[2-4]) and researchers are evaluating within large randomized trials to even omit surgery at all when axillary imaging is negative (SOUNDSentinel node biopsy vs Observation after axillary Ultra-souND, PI and Study Chair O. Gentilini,MD, NCT02167490 and INSEMA- Intergroup-Sentinel-MAmma trial NCT02466737.
While the role of surgery is decreasing, the role of preoperative imaging is increasing. In the future, imaging might even replace surgery in the axillary staging of BC patients, still providing an appropriate level of information to guide medical treatments which are more and more tailored on biology rather than on nodal status. In this context, an unmet need is to achieve the most accurate preoperative imaging assessment of the axilla in order to decide the appropriate treatment for each patient.
The hypothesis of this project is that PET/MRI might provide a single, one-stage, non-invasive, operator independent imaging modality in patients with small BC allowing to select the proper treatment for patients. PET/MRI is a relatively new imaging tool and its field of application is still object of scientific speculation.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 247 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Targeting the Future of Axillary Staging in Early Breast Cancer: A Comparative Study: Sentinel Node Biopsy vs PET/MRI |
| Actual Study Start Date : | July 3, 2020 |
| Estimated Primary Completion Date : | June 16, 2023 |
| Estimated Study Completion Date : | June 30, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: PET/MRI
Patients with early breast cancer up to 3 cm without overt nodal involvement who are candidates to upfront surgery
|
Diagnostic Test: PET/MRI
A consecutive cohort of 247 patients with early BC and no suspicious nodes at both clinical and A-US evaluations and candidates to upfront surgery and SNB will be recruited |
- SNB vs PET/MRI [ Time Frame: Within one month after surgery results from SNB will be available and compared to preoperative PET/MRI ]Results from SNB will be compared to results from PET/MRI
- A secondary outcome is the staging power of PET/MRI compared to preoperative A-US [ Time Frame: At 1 year ]Study will focus on a subgroup of patients having one or two uncertain but no suspicious axillary nodes for which SNB is still indicated. Patient population will be divided into two cohorts: those with completely normal axillary lymph node at AUS and those with 1-2 axillary nodes with uncertain US features. These two groups will be analysed independently. The PET/MRI and AUS results will be compared to each other and ultimately to final pathology, calculating the concordance rate in terms of positive versus negative nodes and number of positive nodes detected by each method. The staging power of both preoperative exams will be evaluated by considering how many times the results from PET/MRI or A-US could have indicated the most appropriate axillary treatment according to pathological findings.
- Correlation between PET/MRI parameters and breast cancer prognosis [ Time Frame: 0 and 36 mths ]Eventual associations between PET/MRI morphological and functional parameters with tumour prognostic features will be investigated.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- signed Informed Consent
- age > 18
- cT < 3 cm
- non palpable lymph nodes
- no suspicious nodes at A-US
- candidate to mastectomy or breast conserving surgery and BLS
Exclusion Criteria:
- pregnancy
- distant metastasis
- inflamatory cancer
- claustrophobia
- allergy to contrast agent
- severe renal insufficiency
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04829643
| Contact: ORESTE D GENTILINI, MD | +39 2643.3939 | gentilini.oreste@hsr.it | |
| Contact: ROSA DI MICCO, MD | dimicco.rosa@hsr.it |
| Italy | |
| Oreste Davide Gentilini | Recruiting |
| Milano, MI, Italy, 20132 | |
| Contact: ORESTE D GENTILINI 0039.2643.3939 gentilini.oreste@hsr.it | |
| Contact: ROSA DI MICCO dimicco.rosa@hsr.it | |
| Sub-Investigator: ROSA DI MICCO | |
| Sub-Investigator: CARLA CANEVARI | |
| Sub-Investigator: PIETRO PANIZZA, Co-PI | |
| Sub-Investigator: ELENA VENTURINI | |
| Principal Investigator: | ORESTE D GENTILINI, MD | Director Breast Unit |
| Responsible Party: | Oreste Davide Gentilini, Head of Breast Unit, Head of Breast Surgery, IRCCS San Raffaele |
| ClinicalTrials.gov Identifier: | NCT04829643 |
| Other Study ID Numbers: |
SNBvsPET/MRI 2 |
| First Posted: | April 2, 2021 Key Record Dates |
| Last Update Posted: | April 2, 2021 |
| Last Verified: | March 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
PET/MRI sentinel node biopsy early breast cancer |
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |